The PR did cover the hottest IPO market we have seen in a long time. T-Cell Immunotherapy. Hands down the hottest IPO you can release this year.
News was known when company inked this deal:
'Initial share placement: Ridgeback will invest approx. A$1.25m in Prima through a placement of 72,206,500 fully paid ordinary shares at A$0.0173 per share. The placement will close on Thursday 14 May 2015 and is not subject to shareholder approval.'
Anyone bothered to look further back at how management views shares? Anyone really dug into the science? How about the small phase II trial, any digging?
Seem to be doing the right things. After the traders move on hope to see the slow march up until they rind the right fit for a drug that is proving itself. You can dig out the real data from all the recent new and it's impressive. Too bad the FDA approval was ambushed by a trial design the FDA did not want to see.
Lots of good data to see. Maybe European approval is possible? Would still need a partner.
Looks like totoal focus is own partnering. A very good move. Buyout possible? Looks like FDA scolding on design of last trial had a major impact. Good Drug with desired characters that FDA could't approve because of trial design. Up to date info even better. (Good partnerships coming).
Impressive results with new colon cancer marker. RCC may even get approval with new data much sooner than FDA
One hit wonder? If they can get the genetic therapy working it means medical science has turned possibly it's biggest corner to date. Last trial, the dosage was grossly inadequate. Does Celladon have the brass ones to design a real trial dosage? So much potential I hope so.
Then we have vultures with accounting situations waiting for final verification of $200M (maybe more) payday and will load up at $2.50 for a quick payday.
I'll wait for my full $3.00/share payoff. Unless DSC looks at the payday that Siga is about to pocket from Bad Faith ill intent and Lawyer fueled compromise that Parsons succumbed too and...then I get my $5/share payday.
FDA rejection was unhappy so much of the phase III data came from (Eastern?) European sites where standard of care varied from US standards.
Also that the crossover allowed invalidated much of the OS. Puzzled me since the focus was PFS in all drugs previously approved in RCC. In fact trials of most were based against placebo.
Maybe the European review will focus on PFS with side effect profile that could make a huge difference in many patients. I'm guessing Tivozanib has a much better chance with the European approval especially with the additional info that has come out.
The RCC phase III trial had impressive results and any potential partner will look as third line approval as almost a sure bet. Get the drug on the market and the advantages will expand the market as the doctors will be fully aware of what is best for their patients (it's not third line). Just get it to market.
GLTA, possible partners can look at all the data and see potential from results that were ignored by the approval committee because of trial design. Partner terms $200M upfront and royalties and milestones? It's an impressive drug.
Also the 3-12-15 News
Potential Biomarker May Indicate Advantage with Tivozanib in Advanced Colorectal Cancer
A potential biomarker called NRP-1 may indicate longer progression-free survival with tivozanib over Avastin for patients with metastatic colorectal cancer.
In the predefined biomarker analysis, patients with low NRP-1 showed an improved PFS compared with those with high NRP-1. Patients with serum NRP-1 levels below the median had longer PFS with tivozanib (17.9 months) compared with Avastin (11.2 months). This demonstrates NRP-1 may be a potential biomarker of tivozanib activity relative to Avastin, according to the researchers.
PFS was shorter in patients with high serum NRP-1 levels (7.3 months with tivozanib versus 7.5 months with Avastin).
The rejection was bizarre. Look at the data and the side effect profile and play doctor. Which drug do you think would be best for you renal cancer patient?
Look at the added PFS Tivozanib will add to patients failing their first therapy and it's a hands down success.
AVEO needs to take their time before considering a partnership and I think there will be many choices. All the competitors with established sales forces would make for home run partners. All partners knowing they would be getting a drug as good or better than theirs and one with a far lower side effect burden. Expect a bidding war.
Avoiding Hand & Foot Syndrome is also a huge advantage. Quality of life should speed use to first line if results pan out. It's going to be a long term investment for me, no idea on the trading side.
Lot of emotion and traders in this stock. Huge positive results turned up in a subgroup and another trial will take a while to prove out. Will not be selling any of my shares at $3.09 after ASCO.
A$13.75m for consideration of an issue of convertible notes which will be convertible into Prima ordinary shares at 2.00 cents per share
Is this a Mafia Stock?
Something smells fishy when they dilute at such low prices a few days before PR. Anyone know history of management?
May 14, 2015
Ridgeback's A$15m investment in Prima will be made in two parts:
An immediate placement of approximately 72 million Prima ordinary shares at 1.73 cents per share ("the Placement"), worth approximately A$1.25m and representing 4.94% of Prima's issued share capital after the placement; and
Subject to obtaining Prima shareholders' approval, a lump sum cash investment of approximately A$13.75m for consideration of an issue of convertible notes which will be convertible into Prima ordinary shares at 2.00 cents per share
* Even considering the conversion to Australian listed shares this is very dilutive financing. If management doesn't address this dilution issue right away it's not good for shareholders.